Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)

Cancer Treatment Reviews

Volumn 40, Issue 4, 2014, Pages 567-577

  Cohen, Roger B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

EGFR; Epidermal growth factor receptor; ErbB1; Head and neck squamous cell carcinoma; Human epidermal growth factor receptor 1; Monoclonal antibodies; Small molecule inhibitors

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; AFATINIB; ALISERTIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMGATUZUMAB; LAPATINIB; LENALIDOMIDE; LINSITINIB; METHOTREXATE; NECITUMUMAB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PLATINUM; TEMSIROLIMUS; VANDETANIB; ZALUTUMUMAB;

ALLERGIC REACTION; ANAPHYLAXIS; ANTISENSE THERAPY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER THERAPY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INDUCTION CHEMOTHERAPY; MONOTHERAPY; MOUTH CANCER; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVENTION; RECURRENT DISEASE; REVIEW; SKIN TOXICITY; WART VIRUS;

EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB1; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 1; MONOCLONAL ANTIBODIES; SMALL MOLECULE INHIBITORS;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84896696623     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.10.002     Document Type: Review

References (113)

1. American Cancer Society Cancer facts and figures, 2013 2013, American Cancer Society, Atlanta, GA.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology™. Head and Neck Cancers. V.2.2013. http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf.
3. Cohen E.E. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006, 24(17):2659-2665.
4. ERBITUX® (cetuximab) injection, for intravenous infusion [package insert]. Branchburg, NJ: ImClone LLC; 2013.
5. Vermorken J.B., Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010, 21(Suppl. 7):vii252-vii261.
6. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
7. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11(1):21-28.
8. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359(11):1116-1127.
9. Ferris R.L., Jaffee E.M., Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010, 28(28):4390-4399.
10. Lee S.C., Srivastava R.M., Lopez-Albaitero A., Ferrone S., Ferris R.L. Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011, 50(2-3):248-254.
11. Namboodiri A.M., Pandey J.P. Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes. Clin Exp Immunol 2011, 166(3):361-365.
12. Lopez-Albaitero A., Lee S.C., Morgan S., et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009, 58(11):1853-1864.
13. Taylor R.J., Chan S.L., Wood A., et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009, 58(7):997-1006.
14. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21(21):3940-3947.
15. Tamura K., Shimizu C., Hojo T., et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011, 22(6):1302-1307.
16. Wheeler D.L., Dunn E.F., Harari P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010, 7(9):493-507.
17. Krumbach R., Schuler J., Hofmann M., Giesemann T., Fiebig H.H., Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 2011, 47(8):1231-1243.
18. Rebucci M., Peixoto P., Dewitte A., et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol 2011, 38(1):189-200.
19. Yonesaka K., Zejnullahu K., Okamoto I., et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011, 3(99):99ra86.
20. Erjala K., Sundvall M., Junttila T.T., et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006, 12(13):4103-4111.
21. Rabinowits G., Haddad R.I. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 2012, 48(11):1085-1089.
22. Fountzilas G., Kalogera-Fountzila A., Lambaki S., et al. MMP9 but not EGFR, MET, ERCC1, P16, and P-53 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol 2009, 2009:305908.
23. Loeffler-Ragg J., Witsch-Baumgartner M., Tzankov A., et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006, 42(1):109-111.
24. Lea I.A., Jackson M.A., Li X., Bailey S., Peddada S.D., Dunnick J.K. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis 2007, 28(9):1851-1858.
25. Cohen E.E., Lingen M.W., Martin L.E., et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005, 11(22):8105-8108.
26. Argiris A., Lee S.C., Feinstein T., et al. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol 2011, 47(10):961-966.
27. Egloff A.M., Grandis J.R. Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. J Oncol 2009, 2009:896407.
28. Licitra L., Mesia R., Rivera F., et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2011, 22(5):1078-1087.
29. Sharafinski M.E., Ferris R.L., Ferrone S., Grandis J.R. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010, 32(10):1412-1421.
30. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004, 22(1):77-85.
31. Burtness B., Goldwasser M.A., Flood W., Mattar B., Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23(34):8646-8654.
32. Goon P.K., Stanley M.A., Ebmeyer J., et al. HPV & head and neck cancer: a descriptive update. Head Neck Oncol 2009, 1:36.
33. Argiris A., Heron D.E., Smith R.P., et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010, 28(36):5294-5300.
34. Psyrri A., Licitra L., De Blas B., Celik I., Vermorken J.B. Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the phase III EXTREME trial. Ann Oncol 2012, 23(Suppl. 9):ix334-ix335. [Abstract 1018O].
35. Vermorken J.B., Stohlmacher-Williams J., Davidenko I., et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013, 14(8):697-710.
36. Ang K.K., Zhang Q.E., Rosenthal D.I., et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011, 29(Suppl.). [Abstract 5500].
37. Ghi M.G., Paccagnella A., Ferrari D., et al. A phase II-III study comparing concomitant chemoradiotherapy (CRT) versus cetuximab/RT (CET/RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Efficacy results (NCT01086826). J Clin Oncol 2013, 31(Suppl.). [Abstract 6003].
38. Kies M.S., Holsinger F.C., Lee J.J., et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010, 28(1):8-14.
39. Brizel D.M., Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol 2006, 24(17):2612-2617.
40. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005, 27(10):843-850.
41. Maubec E., Petrow P., Scheer-Senyarich I., et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011, 29(25):3419-3426.
42. Locati L.D., Bossi P., Perrone F., et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol 2009, 45(7):574-578.
43. Pinto C., Barone C.A., Girolomoni G., et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011, 16(2):228-238.
44. Potthoff K., Hofheinz R., Hassel J.C., et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011, 22(3):524-535.
45. Lacouture M.E., Maitland M.L., Segaert S., et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010, 18(4):509-522.
46. Chung C.H., Mirakhur B., Chan E., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008, 358(11):1109-1117.
47. Li D., Ambrogio L., Shimamura T., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27(34):4702-4711.
48. Solca F., Dahl G., Zoephel A., et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343:342-350.
49. Stewart J.S., Cohen E.E., Licitra L., et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009, 27(11):1864-1871.
50. Argiris A., Ghebremichael M., Gilbert J., et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013, 31(11):1405-1414.
51. Martins R.G., Parvathaneni U., Bauman J.E., et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol 2013, 31(11):1415-1421.
52. Del Campo J.M., Hitt R., Sebastian P., et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011, 105(5):618-627.
53. de Souza J.A., Davis D.W., Zhang Y., et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2012, 18(8):2336-2343.
54. Weiss J., Hayes D.N., Algazy K., et al. Combination lapatinib and capecitabine in advanced, incurable squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2013, 31(Suppl.). [Abstract 6094].
55. Seiwert T.Y., Fayette J., Cupissol D., et al. A randomized, open-label, phase II study of afatinib versus cetuximab in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2012, 23(Suppl. 11):xi35-xi36.
56. Cupissol D., Seiwert T.Y., Fayette J., et al. A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover. J Clin Oncol 2013, 31(Suppl.). [Abstract 6001].
57. Machiels J.-P.H., Licitra L.F., Haddad R.I., et al. LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy. J Clin Oncol 2012, 30(Suppl.). [Abstract TPS5598].
58. Burtness B., Bourhis J., Vermorken J.B., Dai L., Cohen E.E.W. LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients. J Clin Oncol 2012, 30(Suppl.). [Abstract TPS5599].
59. Machiels J.P., Subramanian S., Ruzsa A., et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011, 12(4):333-343.
60. Genmab. Genmab announces zalutumumab update. June 24, 2011. http://files.shareholder.com/downloads/AMDA-KPIBN/2575806801x0x534061/4c7b0ed4-ae2b-4ed2-9284-6e1d38037b42/22%20pipeline%20update_240611_uk.pdf.
61. Ramakrishnan M.S., Eswaraiah A., Crombet T., et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009, 1(1):41-48.
62. Crombet T., Osorio M., Cruz T., et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22(9):1646-1654.
63. Rodriguez M.O., Rivero T.C., del Castillo B.R., et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010, 9(5):343-349.
64. Basavaraj C., Sierra P., Shivu J., Melarkode R., Montero E., Nair P. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. Cancer Biol Ther 2010, 10(7):673-681.
65. Somani N., Karandikar S.M., Bokil K., Bhowmik K.T., Agarwal S. Nimotuzumab with concurrent chemoradiotherapy in patients with locally advanced head and neck cancer (LASCCHN). J Clin Oncol 2013, 31(Suppl.). [Abstract 6084].
66. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001, 38(1):17-23.
67. Wirth L.J., Allen A.M., Posner M.R., et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010, 21(2):342-347.
68. Giralt J., Trigo J.M., Nuyts S., et al. Phase 2, randomized trial (CONCERT-2) of panitumumab (PMAB) plus radiotherapy (PRT) compared with chemoradiotherapy (CRT) in patients (PTS) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Ann Oncol 2012, 23(Suppl. 9):ix334. [Abstract 1016O].
69. Wirth L.J., Dakhil S.R., Kornek G., et al. PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol 2013, 31(Suppl.). [Abstract 6029].
70. Clark P.A., Iida M., Treisman D.M., et al. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia 2012, 14(5):420-428.
71. Kamath A.V., Lu D., Gupta P., et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2012, 69(4):1063-1069.
72. Schaefer G., Haber L., Crocker L.M., et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20(4):472-486.
73. Cervantes-Ruiperez A., Juric D., Hidalgo M., et al. A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: expansion cohorts. J Clin Oncol 2012, 30(Suppl.). [Abstract 2568].
74. Koefoed K., Steinaa L., Soderberg J.N., et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011, 3(6):584-595.
75. Pedersen M.W., Jacobsen H.J., Koefoed K., et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010, 70(2):588-597.
76. Skartved N.J., Jacobsen H.J., Pedersen M.W., et al. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 2011, 17(18):5962-5972.
77. Machiels J.-P.H., Specenier P.M., Krauss J., et al. Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: a proof of concept study. J Clin Oncol 2013, 31(Suppl.). [Abstract 6002].
78. Li S., Kussie P., Ferguson K.M. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008, 16(2):216-227.
79. Paz-Ares L.G., Gomez-Roca C., Delord J.P., et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011, 29(28):3783-3790.
80. Gonzales A.J., Hook K.E., Althaus I.W., et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008, 7(7):1880-1889.
81. Abdul Razak A.R., Soulieres D., Laurie S.A., et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 2012, 24(3):761-769.
82. Audet M.-L., Allo G., Weng X., et al. Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial. J Clin Oncol 2013, 31(Suppl.). [Abstract 6041].
83. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62(16):4645-4655.
84. Limaye S., Riley S., Zhao S., et al. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol 2013, 49(8):835-841.
85. Tan F., Shen X., Wang D., et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012, 76(2):177-182.
86. Fu S., Nemunaitis J.J., Bessudo A., et al. A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer. J Clin Oncol 2012, 30(Suppl.). [Abstract e13101].
87. Niwa H., Wentzel A.L., Li M., Gooding W.E., Lui V.W., Grandis J.R. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 2003, 9(13):5028-5035.
88. He Y., Zeng Q., Drenning S.D., et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998, 90(14):1080-1087.
89. Lai C.J., Bao R., Tao X., et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010, 70(9):3647-3656.
90. Cohen E.E., Davis D.W., Karrison T.G., et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009, 10(3):247-257.
91. Yoo D.S., Kirkpatrick J.P., Craciunescu O., et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res 2012, 18(5):1404-1414.
92. Argiris A., Kotsakis A.P., Hoang T., et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2012, 24(1):220-225.
93. Argiris A., Ohr J., Kubicek G.J., et al. Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2013, 31(Suppl.). [Abstract 6043].
94. Xu M., Mizoguchi I., Morishima N., Chiba Y., Mizuguchi J., Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010, 2010. pii: 832454.
95. van Herpen C.M., van der Voort R., van der Laak J.A., et al. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer 2008, 123(10):2354-2361.
96. van Herpen C.M., van der Laak J.A., de Vries I.J., et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 2005, 11(5):1899-1909.
97. van Herpen C.M., Huijbens R., Looman M., et al. Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. Clin Cancer Res 2003, 9(8):2950-2956.
98. Roda J.M., Joshi T., Butchar J.P., et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007, 13(21):6419-6428.
99. Wu L., Parton A., Lu L., Adams M., Schafer P., Bartlett J.B. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 2011, 60(1):61-73.
100. Lee P., Alvarez R.H., Melichar B., et al. Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: preliminary phase II results. J Clin Oncol 2012, 30(Suppl.). [Abstract 3010].
101. Lu H., Dietsch G.N., Matthews M.A., et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 2012, 18(2):499-509.
102. Jimeno A., Kulesza P., Wheelhouse J., et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007, 96(6):952-959.
103. Bozec A., Etienne-Grimaldi M.C., Fischel J.L., et al. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol 2011, 47(5):340-344.
104. Chung C.H., Wang H., Tsottles N., et al. A phase I study of everolimus in combination with cetuximab and cisplatin as first-line therapy in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2012, 30(Suppl.). [Abstract e16061].
105. Bauman J.E. Arias-Pulido H, Lee SJ, et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol 2013, 49:461-467.
106. Gnoni A., Marech I., Silvestris N., Vacca A., Lorusso V. Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets 2011, 12(4):563-578.
107. Li C., Iida M., Dunn E.F., Wheeler D.L. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol 2010, 97(2):330-337.
108. Brooks H.D., Glisson B.S., Bekele B.N., et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 2011, 117(10):2112-2119.
109. Ihle N.T., Williams R., Chow S., et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004, 3(7):763-772.
110. Ihle N.T., Paine-Murrieta G., Berggren M.I., et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005, 4(9):1349-1357.
111. Saki M, Toulany M, Rodemann HP. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells. Radiother Oncol 2013. [Epub ahead of print].
112. Morris L.G.T., Taylor B.S., Bivona T.G., et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A 2011, 108(47):19024-19029.
113. Krishnamurthyreddy B, Vidyasagar MS, Koteshwar R, et al. A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer.In: Poster presented at: the Annual Meeting of the American Society of Clinical Oncology; May 29-June 7, 2009; Orlando, FL.